Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer

23 Feb 2022

Abstract excerpt

Significance Recent evidence demonstrated the existence of molecular subtypes in pancreatic ductal adenocarcinoma (PDAC), which resist all current therapies. The paucity of therapeutic options, including a complete lack of targeted therapies, underscores the urgent and unmet medical need for the identification of targets and novel treatment strategies for PDAC. Our study unravels a function of the transcription...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Immune cells in cancer
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35197278
DOI: 10.1073/pnas.2105691119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancerPMID 35197278Read ↗

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancerSemantic proximity Read ↗

REST Promotes Pancreatic Ductal Adenocarcinoma Progression by Inhibiting NOXA1/ROS Pathway-Induced Cell PyroptosisSemantic proximity Read ↗

BAP1 regulates HSF1 activity and cancer immunity in pancreatic cancerSemantic proximity Read ↗

The protein phosphatase-2A subunit PR130 is involved in the formation of cytotoxic protein aggregates in pancreatic ductal adenocarcinoma cellsSemantic proximity Read ↗

Combination of RUNX1 inhibitor and gemcitabine to mitigate chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2a-axis-mediated endoplasmic reticulum stressSemantic proximity Read ↗

ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic CancerSemantic proximity Read ↗

PLK1 inhibition enhances gemcitabine-induced apoptosis through PLK1-dependent ERK1/2-BIM and AKT1/NOXA signals in pancreatic cancer cellsSemantic proximity Read ↗

Apoptosis pathways and their therapeutic exploitation in pancreatic cancerSemantic proximity Read ↗

Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair DeficienciesSemantic proximity Read ↗

The protein phosphatase-2A subunit PR130 is linked to cytotoxic protein aggregate formation in mesenchymal pancreatic ductal adenocarcinoma cellsSemantic proximity Read ↗

APE 1/Ref‐1 knockdown in pancreatic ductal adenocarcinoma – characterizing gene expression changes and identifying novel pathways using single‐cell RNA sequencingSemantic proximity Read ↗

Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.